New Antifungals for Vulvovaginal Candidiasis: What Is Their Role?
Candida vulvovaginitis
ibrexafungerp
oteseconazole
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
04 03 2023
04 03 2023
Historique:
received:
31
10
2022
pubmed:
8
1
2023
medline:
9
3
2023
entrez:
7
1
2023
Statut:
ppublish
Résumé
New antifungals, ibrexafungerp and oteseconazole, are now available for treatment of vulvovaginal candidiasis. Both have novel antimicrobial and pharmacokinetic properties and advantages over fluconazole, although comparative trials have involved only placebo. In the absence of allergy, intolerance, and resistance, it is unclear whether these antifungals will replace fluconazole.
Identifiants
pubmed: 36610791
pii: 6970437
doi: 10.1093/cid/ciad002
doi:
Substances chimiques
Antifungal Agents
0
Fluconazole
8VZV102JFY
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
783-785Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Déclaration de conflit d'intérêts
Potential conflicts of interest. J. D. S. has served as an unpaid consultant to and a member of the scientific advisory committees for Mycovia Pharmaceuticals and Synexis Pharmaceuticals; reports payment for presentations from OB-GYN Grand Rounds at Long Island—Stonybrook Medical School; and authored UpToDate articles related to vaginal infections. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.